Recombinant Human Antithrombin (ATryn®) in the Treatment of Patients With DIC Associated With Severe Sepsis
Status:
Terminated
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to explore the efficacy and safety of ATryn®
(antithrombin alfa) for the treatment of disseminated intravascular coagulation (DIC)
associated with severe sepsis, when administered by continuous intravenous (IV) infusion over
five days.